Targeting the SPC25/RIOK1/MYH9 Axis in Ovarian Cancer
Author Information
Author(s): Jiang Xingyu, Yang Muwen, Zhang Weijing, Shi Dongni, Li Yue, He Lixin, Huang Shumei, Chen Boyu, Chen Xuwei, Kong Lingzhi, Pan Yibing, Deng Pinwei, Wang Rui, Ouyang Ying, Chen Xiangfu, Li Jun, Li Zheng, Zou Hequn, Zhang Yanna, Song Libing
Primary Institution: Sun Yat-sen University Cancer Center
Hypothesis
The study investigates the role of the SPC25/RIOK1/MYH9 axis in promoting tumor stemness and platinum resistance in epithelial ovarian cancer.
Conclusion
Targeting the SPC25/RIOK1/MYH9 axis may enhance platinum sensitivity and improve survival in patients with epithelial ovarian cancer.
Supporting Evidence
- SPC25 expression is significantly upregulated in platinum-resistant EOC tissues.
- High SPC25 expression correlates with poor overall survival and progression-free survival in EOC patients.
- Disrupting the SPC25/RIOK1/MYH9 axis enhances platinum efficacy in vitro and in vivo.
Takeaway
This study found that a specific protein complex helps cancer cells resist treatment, and blocking it can make the treatment work better.
Methodology
The study used in vitro and in vivo experiments, including whole-transcriptome sequencing, qRT-PCR, and Western blotting, to analyze the role of the SPC25/RIOK1/MYH9 axis in ovarian cancer.
Limitations
The study primarily focuses on preclinical models, and further clinical validation is needed.
Participant Demographics
447 patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website